Mapping Multiple Sclerosis Genetics Across Global Populations
Multiple sclerosis is a chronic neuroimmunological disorder of the central nervous system with a substantial genetic component. However, much of what is currently known about its genetic architecture has been derived from studies of individuals of European ancestry. This imbalance is scientifically limiting and ethically problematic, because populations of non-European ancestry remain markedly under-represented in genome-wide association studies. The article argues that a global approach to multiple sclerosis genetics is essential, not merely to improve equity in genomic medicine but also to generate a more complete biological understanding of the disease. Without broader ancestral representation, genetic discoveries, risk prediction models, and future precision medicine strategies may fail to benefit all individuals affected by multiple sclerosis.
Genetic Research and Global Epidemiology
The worldwide prevalence of multiple sclerosis varies substantially, with high rates reported in regions such as North America and Europe and lower estimates in parts of Africa, Asia, and Oceania. Although some of this variation may reflect differences in diagnosis, access to neurological care, and health data infrastructure, genetic factors may also contribute. The article emphasizes that studying multiple sclerosis genetics across populations could help distinguish true biological differences from ascertainment bias. Migrant studies are particularly informative because they show that environmental exposures, especially those occurring before adolescence, can modify disease risk. A more complete genetic map across ancestries could therefore improve understanding of how genes and environment jointly shape global multiple sclerosis epidemiology.
The Major Histocompatibility Complex as a Central Genetic Region
The major histocompatibility complex, especially the HLA region on chromosome 6, is the strongest known genetic contributor to multiple sclerosis susceptibility. In European populations, HLA-DRB1*15:01 is a major risk allele, while several other HLA class I and class II alleles either increase or reduce risk. However, the frequency and structure of HLA haplotypes differ greatly between ancestral populations. Some alleles that are rare or absent in Europeans, such as HLA-DRB1*04:05 and HLA-DRB1*15:03, have been associated with multiple sclerosis in Japanese, African, Brazilian, Iranian, and other populations. Studying these differences can clarify which immune pathways are shared across populations and which may be ancestry-specific.
Cross-Ancestral Fine Mapping and Causal Variant Discovery
One of the most important scientific advantages of multi-ancestry genetics is improved fine mapping. Many variants identified in genome-wide association studies are not themselves causal; instead, they are correlated with causal variants through linkage disequilibrium. Because linkage disequilibrium patterns differ across populations, combining data from multiple ancestries can narrow the set of plausible causal variants. This is especially valuable in populations of African ancestry, where shorter linkage disequilibrium blocks can improve genetic resolution. The article highlights that cross-ancestral fine mapping has already advanced research in other complex diseases and traits, and it could similarly help identify the causal mechanisms underlying multiple sclerosis susceptibility loci.
Beyond the MHC: Shared and Population-Specific Risk Architecture
Outside the major histocompatibility complex, many multiple sclerosis risk variants discovered in European populations appear to have broadly similar effects in other ancestral groups. Nevertheless, the article cautions that detecting genuine differences in genetic effects across populations is statistically challenging. Differences in allele frequency, linkage disequilibrium, sample size, and genotyping array design can all influence results. Some studies in African American and Hispanic cohorts have suggested possible ancestry-related heterogeneity at loci involving immune signaling, vitamin D pathways, and B-cell biology. These findings remain preliminary, but they demonstrate the potential for diverse genetic studies to uncover both shared disease mechanisms and population-specific risk signals.
Phenotypic Variation, Severity, and Clinical Relevance
Multiple sclerosis is clinically heterogeneous, with variation in age at onset, relapse frequency, disability progression, inflammatory activity, and treatment response. Existing genetic studies have explained only a small proportion of this phenotypic variation. The article argues that studying populations with different disease patterns may reveal genetic determinants of severity and progression. Epidemiological data suggest that individuals of African and Hispanic ancestry may experience earlier onset or more aggressive disease courses in some settings, although social determinants of health, diagnostic delays, and unequal access to care must be carefully considered. Integrating genetics with high-quality clinical data could help distinguish biological contributors from structural inequities and improve care for all patients.
Ethical, Logistical, and Scientific Imperatives
Expanding multiple sclerosis genetics research to under-represented populations presents practical challenges, including recruitment, cost, statistical power, appropriate control selection, and the need for better analytical tools. It also requires careful ethical practice, including sustained collaboration with local researchers, meaningful patient involvement, transparent communication, and respect for communities that have historically been harmed by biomedical research. Despite these challenges, the article makes a strong case that inclusive genetics is both a scientific necessity and an ethical obligation. Consortium-scale studies involving diverse populations could improve causal discovery, refine polygenic risk prediction, clarify gene–environment interactions, and ensure that future advances in genomic medicine benefit people with multiple sclerosis worldwide.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Jacobs, B.M., Peter, M., Giovannoni, G. et al. Towards a global view of multiple sclerosis genetics. Nat Rev Neurol 18, 613–623 (2022). https://doi.org/10.1038/s41582-022-00704-y
